Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECUR-AF
2024-513719-28-00Phase 4Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in Atrial fibrillation (AFib) (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Time to recurrence of atrial fibrillation within 30 days after cardioversion. Planned start Jun 2025; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2024-513719-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513719-28-00.